UBS upgrades Agilent on China, pharma lab demand; sees 20%+ upside
PositiveFinancial Markets

UBS has upgraded its rating on Agilent Technologies, citing strong demand in China and the pharmaceutical lab sector. This upgrade suggests that UBS sees significant potential for Agilent, projecting over a 20% upside in its stock price. This is important as it reflects confidence in Agilent's growth prospects, particularly in a market that is increasingly focused on healthcare and pharmaceuticals.
— Curated by the World Pulse Now AI Editorial System